Chesapeake Research Group Helps Fight Opioid Epidemic
BALTIMORE, Jan. 8, 2018 /PRNewswire/ -- Chesapeake Research Group, CRG, is enrolling patients in clinical research studies for investigational medications that are used to treat post-operative pain. These medications could help combat America's opioid epidemic.
CRG is enrolling patients who suffer from discomfort due to bunions for one of its studies. Like virtually all patients across the country, bunion removal patients are frequently prescribed opioids after surgery. Every time a patient is prescribed an opioid, there is a risk for addiction. CRG is researching an alternative to this practice.
These patients undergo bunion removal surgery on site at CRG. Instead of opioids they are given an investigational extended release numbing drug. This drug has the potential to greatly reduce or alleviate the need for narcotic pain medications after surgery. Essentially, patients can undergo bunion removal surgery without the added risk of taking opioids for postoperative pain management.
According to CRG Medical Director Dr. Ira Gottlieb, "We all know how deadly the opioid epidemic is. America is truly in a crisis as the epidemic quickly spreads. Drug overdoses are now the leading cause of death among Americans under 50 years old. Per the Centers for Disease Control, after decades of increase, life expectancy among Americans has fallen for the second year in a row as the opioid crisis continues to drive up overall death rates in the United States."
He continued, "At CRG we are conducting research to fight this crisis. What we are learning from these studies is not limited to just post-op bunionectomy patients. The information we are gathering has the potential to benefit patients after all types of surgery and with all sorts of pain management issues."
CRG works alongside pharmaceutical companies that are developing medications to reduce the need for opioids after surgery or to eliminate their use altogether. It was founded in 2004 by Dr. Ira Gottlieb, DPM and Deborah Tunick, RN, CCRC. The clinical study investigative site is dedicated to supporting its clients in the development of products by conducting rigorous and efficient clinical drug/ device studies. CRG has completed over 60 pain related studies in its 10,0000-square foot state-of-the-art facility in Pasadena Maryland. The facility encompasses their Research Facility, Surgery Centers and Foot & Ankle Center. The facility has multiple treatment rooms and overnight capabilities for 15 research participants.
Veida McCampbell
Chesapeake Research Group
310-614-0083
[email protected]
SOURCE Chesapeake Research Group, LLC
Share this article